AnaptysBio (NASDAQ:ANAB) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Insider and Institutional Ownership
80.4% of Bristol-Myers Squibb shares are held by institutional investors. 14.0% of AnaptysBio shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of current ratings and recommmendations for AnaptysBio and Bristol-Myers Squibb, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AnaptysBio presently has a consensus price target of $102.86, indicating a potential upside of 174.51%. Bristol-Myers Squibb has a consensus price target of $56.86, indicating a potential downside of 0.17%. Given AnaptysBio’s stronger consensus rating and higher possible upside, research analysts plainly believe AnaptysBio is more favorable than Bristol-Myers Squibb.
Volatility and Risk
AnaptysBio has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
This table compares AnaptysBio and Bristol-Myers Squibb’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Bristol-Myers Squibb pays an annual dividend of $1.64 per share and has a dividend yield of 2.9%. AnaptysBio does not pay a dividend. Bristol-Myers Squibb pays out 41.2% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares AnaptysBio and Bristol-Myers Squibb’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AnaptysBio||$5.00 million||202.70||-$61.66 million||($2.50)||-14.99|
|Bristol-Myers Squibb||$22.56 billion||4.11||$4.92 billion||$3.98||14.31|
Bristol-Myers Squibb has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.
Bristol-Myers Squibb beats AnaptysBio on 10 of the 16 factors compared between the two stocks.
AnaptysBio Company Profile
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.